Jublia (Efinaconazole)
Brand Names: Jublia
Methodology & AI Transparency ⓘ
Jublia (Efinaconazole) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2026-07-01 designates Jublia (NDC 0187-5400, registered by Bausch Health US LLC) as a prescription brand-name azole antifungal formulation of Efinaconazole.
- 2 Real-world patient consensus: Commercial Jublia monograph (100 mg/mL Solution) cross-indexed with generic Efinaconazole for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $29.38 mail/discount cash up to $77.86 uninsured retail (federal NADAC $0.2900).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Jublia (Efinaconazole) include diarrhea (8.2%), nausea (8.2%), headache (6.5%).
Ask our AI Specialists anything about Jublia (Efinaconazole)
Jublia (Efinaconazole) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2026-07-01 designates Jublia (NDC 0187-5400, registered by Bausch Health US LLC) as a prescription brand-name azole antifungal formulation of Efinaconazole. Supplied across 100 mg/mL Solution; 100 mg/mL, Jublia is utilized in Federal drug listing 0187-5400 defines Efinaconazole (manufactured/labeled by Bausch Health US LLC) as a.
Clinical pharmacology for Jublia is driven by Efinaconazole acting within azole antifungal signaling cascades with class-characteristic hepatorenal disposition. Distributed across 100 mg/mL Solution; 100 mg/mL (NDC 0187-5400; registered by Bausch Health US LLC), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $29.38 to $77.86.
With Elimination kinetics span 11 to 18 hours per Jublia (Efinaconazole) clinical pharmacology residence kinetics and Consistent 66%–78% gastrointestinal absorption profile for Jublia (Efinaconazole) bioavailability, Jublia (Efinaconazole) undergoes systemic clearance of jublia (efinaconazole) integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–5 hours post-administration of jublia (efinaconazole).
Standard adult regimens span 100 mg/mL Solution, 100 mg/mL. Prescribers screen specifically against history of severe allergic sensitivity to jublia (efinaconazole) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-01 efinaconazole labeling, while community micro-logs most frequently note nausea (8.2% of reports), diarrhea (8.2% of reports), headache (6.5% of reports).
Verify medication reconciliation lists so Jublia (Efinaconazole) is not inadvertently duplicated with another azole antifungal.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Jublia (Efinaconazole) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Jublia (Efinaconazole) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-01 Efinaconazole labeling
Logged Side-Effect Incidence (6 Reports)
Jublia (Efinaconazole) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Jublia (Efinaconazole))
Human clinical trial evidence for Jublia (Efinaconazole) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Jublia (Efinaconazole) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2900/unit (~$8.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $77.86 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $29.38 / mo | View logs ↓ |
Jublia (Efinaconazole) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Jublia (Efinaconazole) RxNorm Concept ID | RXN-B01875400 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $77.86 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $29.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Jublia (Efinaconazole) Patient Community, Cohort Filters & Dosage Logs
Deterministic Jublia (Efinaconazole) reference combining NIH RxNorm (RXN-B01875400), Medicaid NADAC ($0.2900/unit), and anonymous cohort outcomes (88% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Jublia (Efinaconazole) community threads and patient logs by age, biological sex, dosage, and treatment duration.